Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years
Authors' conclusion
In our study, OS results efficacy in non-elderly and elderly patients, making it an effective treatment option also for very elderly type 2 diabetic patients.
Study context
- Population
- Patients with T2D starting oral semaglutide (OS) between October 2021 and December 2023 in seven diabetes centers18.7 % >75 yr
- Participants
- 1,824 patients
- Exposure
- Before vs after oral semaglutide initiation, by age group
- Outcome
- Change in HbA1c and body weight, total sample
- Follow-up
- 6 (T6) and 12 (T12) months
Main finding
As reported in the abstract
6 (T6) and 12 (T12) months
HbA1c reduction at T6 and at T12 (both p < 0.0001)
0.87 %
Body weight reduction at T6 (p < 0.0001)
2.78 Kg
Body weight reduction at T12 (p < 0.0001)
3.89 Kg
Observational data: associations, not effects.
Further findings
HbA1c and body weight in >75 yr · T6 and T12
- Body weight change at T6 (p = 0.0003)
- −1.57 Kg
- Body weight change at T12 (p < 0.0001)
- −2.74 Kg
- Body weight reduction, p for interaction
- 0.005
- HbA1c reduction at T6 (p < 0.0001)
- HbA1c reduction at T12 (p = 0.0003)
Original publication
Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years. Diabetes Res Clin Pract. Published 12 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →